# Evidence Summary EGCG is the main anticancer catechin in **green tea**, and the evidence base around EGCG is much larger than most natural compounds used in oncology. ### Research Overview 1. Extensive preclinical data across breast, colorectal, lung, prostate, pancreatic, haematologic, oral, and ovarian cancer models 2. Multiple Phase I and Phase II trials in prevention, biomarker, and treatment-support settings 3. Strong epidemiological signals linking regular green tea intake to reduced cancer risk in several cancers 4. Review and meta-analytic literature supports chemopreventive and adjunctive potential 5. Large Phase III oncology treatment trials remain limited ### Clinical Application Status **Approved status:** Not approved as a cancer drug. Marketed as a dietary supplement and widely consumed in green tea. **Clinical use:** Used in integrative oncology for prevention-oriented support, immune and inflammatory modulation, and treatment-support discussions. **Evidence strength:** Strong preclinical evidence with early but meaningful human support. Best positioned as adjunctive or chemopreventive rather than monotherapy. ### Key Advantages 1. **Multi-target activity** — affects EGFR, MAPK, PI3K/Akt, mTOR, apoptosis, angiogenesis, and metastasis-related biology 2. **Strong epidemiological support** — green tea intake has been linked to reduced risk or recurrence signals in several settings 3. **Immune relevance** — supports interest in NK cells, macrophages, dendritic cells, and tumour-microenvironment signalling 4. **Broader health relevance** — may also support metabolic, cardiovascular, and antimicrobial goals relevant to cancer patients 5. **Combination potential** — has preclinical synergy data with selected taxanes, platinum drugs, anthracyclines, and 5-FU ### Key Considerations 1. **Bioavailability is poor** — oral systemic exposure is limited 2. **Most human data is not late-stage treatment data** — prevention and support remain stronger areas 3. **Drug interactions matter** — CYP and P-glycoprotein issues need review 4. **Bortezomib is a major caution** — EGCG may antagonise its proteasome-inhibition mechanism 5. **Rare hepatotoxicity has been reported with high-dose extracts** — especially concentrated products taken on an empty stomach ### Bottom line EGCG is one of the most credible natural oncology adjuncts from a research-volume perspective. Its best current role is as a complement to standard care, especially in prevention-oriented, inflammatory, metabolic, and pathway-focused contexts. ### Key References Anticancer Molecular Mechanisms of Epigallocatechin-3-Gallate (EGCG)\ Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications\ Dietary EGCG: State-of-the-Art in Anticancer Research\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/evidence-summary.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.